

IN THE SPECIFICATION

On page 14 of the specification – please replace the second paragraph beginning with “*The following peptides...*” and ending with “*...Gly Gln Asn*”, with the following replacement paragraph containing the peptide sequences and identifiers:

-- The following peptides were employed:

SEQ ID NO: 1 Ala Arg Asn Leu Val Pro Met Val Ala
SEQ ID NO: 2 Arg Asn Leu Val Pro Met Val Ala Thr
SEQ ID NO: 3 Asn Leu Val Pro Met Val Ala Thr Val
SEQ ID NO: 4 Leu Val Pro Met Val Ala Thr Val Gln
SEQ ID NO: 5 Val Pro Met Val Ala Thr Val Gln Gly
SEQ ID NO: 6 Pro Met Val Ala Thr Val Gln Gly Gln
SEQ ID NO: 7 Met Val Ala Thr Val Gln Gly Gln Asn --

CONDITIONAL PETITION FOR EXTENSION OF TIME

If any extension of time for this response is required, Applicants request that this be considered a petition therefore. Please charge the required fee to Deposit Account No. 14-1263.

ADDITIONAL FEES

Please charge any further insufficiency of fees, or credit any excess to Deposit Account No. 14-1263.


REMARKS

In response to the Notice of Sequence Compliance Applicants request entry of the foregoing amendment.

The amendment directs that the indicated paragraph on page 14 of the specification be replaced with replacement paragraph submitted herewith. The peptides on page 14 are now listed with proper sequence identifiers according to PTO guidelines.

These amendments do not add new matter.

Respectfully submitted,
NORRIS, McLAUGHLIN & MARCUS

A handwritten signature in black ink, appearing to read "Theodore A. Gottlieb", written over a horizontal line.

Theodore A. Gottlieb
Reg. No. 42,597
220 East 42nd Street
New York, NY 10017
telephone (646) 487-5675
facsimile (212) 808-0844



MARKED UP VERSION OF REPLACEMENT PARAGRAPH

RECEIVED
NOV 13 2002
TECH CENTER 1600/2900

-- The following peptides were employed:

- 1) SEQ ID NO: 1 Ala Arg Asn Leu Val Pro Met Val Ala
- 2) SEQ ID NO: 2 Arg Asn Leu Val Pro Met Val Ala Thr
- 3) SEQ ID NO: 3 Asn Leu Val Pro Met Val Ala Thr Val
- 4) SEQ ID NO: 4 Leu Val Pro Met Val Ala Thr Val Gln
- 5) SEQ ID NO: 5 Val Pro Met Val Ala Thr Val Gln Gly
- 6) SEQ ID NO: 6 Pro Met Val Ala Thr Val Gln Gly Gln
- 7) SEQ ID NO: 7 Met Val Ala Thr Val Gln Gly Gln Asn --




CLEAN COPY OF REPLACEMENT PARAGRAPH

RECEIVED
NOV 13 2002
TECH CENTER 1600/2900

-- The following peptides were employed:

- SEQ ID NO: 1 Ala Arg Asn Leu Val Pro Met Val Ala
- SEQ ID NO: 2 Arg Asn Leu Val Pro Met Val Ala Thr
- SEQ ID NO: 3 Asn Leu Val Pro Met Val Ala Thr Val
- SEQ ID NO: 4 Leu Val Pro Met Val Ala Thr Val Gln
- SEQ ID NO: 5 Val Pro Met Val Ala Thr Val Gln Gly
- SEQ ID NO: 6 Pro Met Val Ala Thr Val Gln Gly Gln
- SEQ ID NO: 7 Met Val Ala Thr Val Gln Gly Gln Asn --



- 14 -

RECEIVED

NOV 13 2002

TECH CENTER 1600/2900

Prot PO6725) having a length of 15 amino acids (~~Ala Arg Asn Leu Val Pro~~ Met Val Ala Thr Val Gln Gly Gln Asn, pp65⁴⁹³⁻⁵⁰⁷). This protein fragment is known to be capable of inducing HLA-A2 restricted cytotoxic T cells in a bulk culture, i.e., to contain a T-cell epitope presented with HLA-A2 (M.R. Wills et al. (1996), J. Virol. Vol. 70, pp 7569-5779). The length of 9 amino acids for the fragments to be tested was chosen because this is the typical length of epitopes presented with MHC class I molecules (H.G. Rammensee et al. (1995), Immunogenetics, Vol. 41, pp 178-228). The peptides used respectively overlap by 8 amino acids, for successive peptides, and thus comprise all possible fragments of this length. The peptides were employed as a mixture of all peptides or singly. The peptide concentration in the Example shown was 1 µg/ml for each peptide.

The following peptides were employed:

- 1) Ala Arg Asn Leu Val Pro Met Val Ala
- 2) Arg Asn Leu Val Pro Met Val Ala Thr
- 3) Asn Leu Val Pro Met Val Ala Thr Val
- 4) Leu Val Pro Met Val Ala Thr Val Gln
- 5) Val Pro Met Val Ala Thr Val Gln Gly
- 6) Pro Met Val Ala Thr Val Gln Gly Gln
- 7) Met Val Ala Thr Val Gln Gly Gln Asn

Replace this
paragraph with
amended replace-
ment paragraph.
TC.

Incubations with the mixture of all peptides (Figure: upper left diagram) and with peptide 3 alone, (Figure: middle column, second diagram from above) resulted in the production of IFN-γ in T cells, detected by measurement in a flow cytometer on the individual cell level (J.L. Picker et al. (1995), Blood, Vol. 86, pp 1408-1419). None of the other individually tested peptides had this effect. A study published in the literature identified exactly the same epitope within the same protein segment by conventional